The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Venlafaxine Extended Release in Posttraumatic Stress Disorder: A Sertraline- and Placebo-controlled Study
Abstract
This 12-week, double-blind, multicenter trial evaluated the efficacy of venlafaxine extended release (ER), sertraline, and placebo in adult outpatients (N = 538) with a primary diagnosis of posttraumatic stress disorder (PTSD), as defined in the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, symptoms for 6 months or more and 17-item Clinician-administered PTSD Scale (CAPS-SX17) score of 60 or more. Patients were randomly assigned to receive placebo or flexible doses of venlafaxine ER (37.5-300 mg/d) or sertraline (25-200 mg/d) for 12 weeks or less. The primary outcome was the baseline-to-end point change in total CAPS-SX17 score (last observation carried forward). Secondary measures included CAPS-SX17 symptom cluster scores for reexperiencing/intrusion, avoidance/numbing, and hyperarousal; frequency of remission (CAPS-SX17 < or =20); and changes in Davidson Trauma Scale total score and symptom cluster scores for avoidance/numbing, hyperarousal, and reexperiencing/intrusion. Mean changes in CAPS-SX17 scores were -41.8, -39.4, and -33.9 for venlafaxine ER (P < 0.05 vs. placebo), sertraline, and placebo, respectively. Mean changes for venlafaxine ER, sertraline, and placebo in CAPS-SX17 cluster scores were -13.0, -11.7, and -11.0 for reexperiencing; -17.1, -16.8, and -13.7 (P < 0.05 both active treatments vs. placebo) for avoidance/numbing; and -11.8, -10.9, and -9.2 (P < 0.05 venlafaxine vs. placebo) for hyperarousal. Week 12 remission rates were venlafaxine ER 30.2% (P < 0.05 vs. placebo), sertraline 24.3%, and placebo 19.6%. The venlafaxine ER group had significantly better Davidson Trauma Scale total and cluster scores than placebo. Mean maximum daily doses were 225-mg venlafaxine ER and 151-mg sertraline. Both treatments were generally well tolerated. Study results suggest that venlafaxine ER is effective and well tolerated in the short-term treatment of PTSD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Studies of the pharmacological treatment of PTSD on other groups of trauma-affected patients have pointed towards the selective Serotonine-Noradrenaline reuptake inhibitor (SNRI) venlafaxine as an alternative treatment option [17].”
From Treatment of trauma-affected refugees with venlafaxine versus sertraline combined with psychotherapy - a randomised study (2016) · cites this paper as [17]
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
Posttraumatic Stress Disorder in the National Comorbidity Survey
Kessler, R. C. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240066012 · Cited by 10,379
The development of a Clinician-Administered PTSD Scale
Blake, D. D., Weathers, F. W., Nagy, L. M., Kaloupek, D. G., Gusman, F. D., Charney, D. S., & Keane, T. M. (1995) · Journal of Traumatic Stress · doi:10.1002/jts.2490080106 · Cited by 5,024
Traumatic Events and Posttraumatic Stress Disorder in an Urban Population of Young Adults
Breslau, N. (1991) · Archives of General Psychiatry · doi:10.1001/archpsyc.1991.01810270028003 · Cited by 2,544
(1993) · PubMed · Cited by 1,900
Resnick, H. S., Kilpatrick, D. G., Dansky, B. S., Saunders, B. E., & al, E. (1993) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.61.6.984 · Cited by 1,868
Resnick, H. S., Kilpatrick, D. G., Dansky, B. S., Saunders, B. E., & Best, C. L. (1993) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.61.6.984 · Cited by 1,868
Posttraumatic stress disorder: the burden to the individual and to society.
Kessler, R. C. (2000) · PubMed · Cited by 1,445
Assessment of a new self-rating scale for post-traumatic stress disorder
Davidson, J. R. T., Book, S. W., Colket, J. T., Tupler, L. A., ROTH, S., DAVID, D., Hertzberg, M. A., Mellman, T. A., Beckham, J. C., Smith, R., et al. (1997) · Psychological Medicine · doi:10.1017/s0033291796004229 · Cited by 983
Self-citation
Cited by
Sorted by citations
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Antidepressants (SSRIs & SNRIs): Evidence from metaanalyses [895,1060] and RCTs supports the use of the SSRI paroxetine [966-970] and the SNRI venlafaxine XR [975,989] (both Level 1) for the first-line treatment of PTSD.”
ResultInfluentialBaldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
Pharmacotherapy for post traumatic stress disorder (PTSD)
Stein, D. J., Ipser, J. C., Seedat, S., Sager, C., & Amos, T. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002795.pub2 · Cited by 519
Lee, D. J., Schnitzlein, C. W., Wolf, J. P., Vythilingam, M., Rasmusson, A. M., & Hoge, C. W. (2016) · Depression and Anxiety · doi:10.1002/da.22511 · Cited by 416
Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD)
Ipser, J. C., & Stein, D. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001209 · Cited by 216
Pharmacotherapy of anxiety disorders: A critical review
Koen, N., & Stein, D. J. (2011) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2011.13.4/nkoen · Cited by 151
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Hoskins, M. D., Bridges, J., Sinnerton, R., Nakamura, A., Underwood, J. F. G., Slater, A., Lee, M. R. D., Clarke, L., Lewis, C., Roberts, N. P., et al. (2021) · European Journal of Psychotraumatology · doi:10.1080/20008198.2020.1802920 · Cited by 127
Bailey, C. R., Cordell, E., Sobin, S. M., & Neumeister, A. (2013) · CNS Drugs · doi:10.1007/s40263-013-0051-4 · Cited by 89
Bajor, L. A., Ticlea, A. N., & Osser, D. N. (2011) · Harvard Review of Psychiatry · doi:10.3109/10673229.2011.614483 · Cited by 76
Sonne, C., Carlsson, J., Bech, P., Elklit, A., & Mortensen, E. L. (2016) · BMC Psychiatry · doi:10.1186/s12888-016-1081-5 · Cited by 56
“Studies of the pharmacological treatment of PTSD on other groups of trauma-affected patients have pointed towards the selective Serotonine-Noradrenaline reuptake inhibitor (SNRI) venlafaxine as an alternative treatment option [17].”
BackgroundTwo weeks of pretreatment with escitalopram facilitates extinction learning in healthy individuals
Bui, E., Orr, S. P., Jacoby, R. J., Keshaviah, A., LeBlanc, N. J., Milad, M. R., Pollack, M. H., & Simon, N. M. (2013) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2330 · Cited by 42
Bajor, L. A., Balsara, C., & Osser, D. N. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114840 · Cited by 43
Advances in the management of treatment-resistant anxiety disorders
Lanouette, N. M., & Stein, M. B. (2010) · Focus · doi:10.1176/foc.8.4.foc501 · Cited by 15
Barhoma, M., Carlsson, J., & Sonne, C. (2024) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2024.2324357 · Cited by 1
Metadata
- Authors
- Davidson, J., Rothbaum, B. O., Tucker, P., Asnis, G., Benattia, I., & Musgnung, J. J.
- Affiliations
- Duke University (US)
- Emory University (US)
- OU Health (US)
- Albert Einstein College of Medicine (US)
- Wyeth (US)
- Corresponding author
- Davidson, Jonathan
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 2006-06
- Volume
- 26
- Issue
- 3
- Pages
- 259-267
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2066358721
- Cited by
- 157
- References
- 41
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 10 · 2023: 6 · 2022: 8 · 2021: 3 · 2020: 6 · 2019: 3 · 2018: 6 · 2017: 8 · 2016: 8 · 2015: 10 · 2014: 9 · 2013: 9 · 2012: 9
- FWCI
- 13.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Clinical Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Social Sciences › Psychology › Clinical Psychology › Migration, Health and Trauma
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- post-traumatic stress disorder, sertraline, selective serotonin reuptake inhibitors, antidepressant efficacy, symptom remission, re-experiencing, avoidance and numbing, hyperarousal, outpatients, flexible dosing, Davidson Trauma Scale, treatment-resistant PTSD, adverse events
- MeSH terms
- Venlafaxine Hydrochloride, Adolescent, Adult, Cyclohexanols, Delayed-Action Preparations, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Stress Disorders, Post-Traumatic, Antidepressive Agents, Second-Generation, Sertraline
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review